New Directions in Cancer Immunotherapy

If you’re interested in live presentations about the latest cancer research, all roads lead to the annual meeting of the AACR. In this brief review of the meeting’s proceedings, we will not attempt anything like exhaustive coverage. Instead, we focus on cancer immunotherapy’s recent advances include conditionally activated cytokines, inhibitors of key kinases, pathway-bridging bispecific antibodies, and endurant CAR T cells.